Mirtazapina Flas Normogen (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Flas Normogen, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It treats major depressive disorder in adult patients. GNH USA supplies Mirtazapina Flas Normogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a NaSSA antidepressant used primarily in the management of depressive disorders. - Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Depressive episodes associated with anxiety: alleviates co‑existing anxiety and depressive signs. - Treatment‑resistant depression (adjunct): may be added when first‑line agents are insufficient.

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Suicidal thoughts or behavior - Severe hypotension - Hepatic dysfunction - Serotonin syndrome when combined with other serotonergic agents

When prescribing or dispensing mirtazapine, consider the following safety measures. - Hepatic function: assess liver status before initiation. - Suicidal ideation: monitor patients, especially early in treatment. - Elderly patients: use lower doses to reduce sedation risk. - Discontinuation: taper gradually to avoid withdrawal symptoms. - Concomitant CNS depressants: avoid excessive sedation. - Store at below 25°C: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase plasma levels. - Other serotonergic agents (e.g., tramadol, linezolid): risk of serotonin syndrome. - Alcohol or other CNS depressants: enhanced sedation. - Drugs that prolong QT interval: additive cardiac risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise concentrations modestly. - Antihypertensive agents: possible additive blood‑pressure lowering effect. - Anticholinergic medications: may worsen dry mouth and constipation.